1 February 2021 in PLOS Genetics
The piRNA pathway is a highly conserved mechanism to repress transposon activation in the germline in Drosophila and mammals. This pathway starts from transcribing piRNA clusters to generate long piRNA precursors. The majority of piRNA clusters lack conventional promoters, and utilize heterochromatin- and HP1D/Rhino-dependent noncanonical mechanisms for transcription. However, information regarding the transcriptional regulation of piRNA clusters is limited. Here, we report that the Drosophila acetyltransferase Enok, which can activate transcription by acetylating H3K23, is critical for piRNA production from 54% of piRNA clusters including 42AB, the major piRNA source. Surprisingly, we found that Enok not only promotes rhino expression by acetylating H3K23, but also directly enhances transcription of piRNA clusters by facilitating Rhino recruitment. Taken together, our study provides novel insights into the regulation of noncanonical transcription at piRNA clusters and transposon silencing.
9 November 2026 in EMBO Molecular Medicine
Driver mutations that activate upstream Hedgehog (Hh) signaling are well-known to initiate basal cell carcinoma (BCC); however, the role of recurrent secondary mutations is less well understood. Here, we performed spatial transcriptomics to show that nascent murine BCC-like tumors are initially comprised of two subpopulations that differ in expression of Hh, stem cell, and differentiation markers. Using a newly developed cell culture formulation that we termed “RRi conditions”, we established several mouse BCC cell lines, benchmarked them against existing ASZ BCC cells, and identified novel genes associated with Hh activation ( Wnt7b , Tgfb3 , Cxcl14 ). We further show that inducible N-MYC expression promotes an NICD low ;K10 low ;Ki67+ undifferentiated cell state, similar to that of transit-amplifying hair follicle progenitors, and that genetically ablating N-Myc blunts tumor formation in mice. Finally, we report that an immunomodulatory drug, imiquimod, regresses nascent lesions and destabilizes N-MYC protein, an effect that depends upon GSK3 and proteasome activity. Altogether, our findings demonstrate that BCCs upregulate N-MYC to maintain a proliferative progenitor-like cell state, and support the use of imiquimod to restrict tumor progression.